Recent advances in the biology of bone tumors and new diagnostic tools

Bone Cancer

Volumn , Issue , 2010, Pages 225-234

  De Pinieux, Gonzague ^a   Bouvier, Corinne ^a  

^a UNIVERSITÉ DE TOURS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 80052676155     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-374895-9.00019-0     Document Type: Chapter

References (56)

1. O'Connell J.X., Nanthakumar S.S., Nielsen G.P., et al. Osteoid osteoma: the uniquely innervated bone tumor. Mod Pathol 1998, 1:175-180.
2. Lucas D.R., Unni K.K., McLeod R.A., et al. Osteoblastoma: clinicopathologic study of 306 cases. Hum Pathol 1994, 25:117-134.
3. Szymanska J., Mandahl N., Mertens F., et al. Ring chromosomes in parosteal osteosarcoma contain sequences from 12q13-15: a combined cytogenetic and comparative genomic hybridization study. Genes Chromosomes Cancer 1996, 16:31-34.
4. Wunder J.S., Eppert K., Burrow S.R., et al. Co-amplification and overexpression of CDK4, SAS and MDM2 occurs frequently in human parosteal osteosarcomas. Oncogene 2000, 18:783-788.
5. Park H.R., Jung W.W., Bertoni F., et al. Molecular analysis of p53, MDM2 and H-ras genes in low-grade central osteosarcoma. Pathol Res Pract 2004, 200:439-445.
6. Bunting K.D., Hawley R.G. Integrative molecular and developmental biology of adult stem cells. Biol Cell 2003, 95:563-578.
7. Mintz M.B., Sowers R., Brown K.M., et al. An expression signature classifies chemotherapy-resistant pediatric osteosarcoma. Cancer Res 2005, 65:1748-1754.
8. Scotlandi K., Manara M.C., Hattinger C.M., et al. Prognostic and therapeutic relevance of HER2 expression in osteosarcoma and Ewing's sarcoma. Eur J Cancer 2005, 41:1349-1361.
9. Okada K., Hasegawa T., Yokoyama R., et al. Prognostic relevance of rosette-like features in osteosarcoma. J Clin Pathol 2003, 56:831-834.
10. Khanna C., Khan J., Nguyen P., Prehn J., et al. Metastasis-associated differences in gene expression in a murine model of osteosarcoma. Cancer Res 2001, 61:3750-3759.
11. Khanna C., Wan X., Bose S., et al. The membrane-cytoskeleton linker ezrin is necessary for osteosarcoma metastasis. Nat Med 2004, 10:182-186.
12. Kim M.S., Song W.S., Cho W.H., et al. Ezrin expression predicts survival in stage IIB osteosarcomas. Clin Orthop Relat Res 2007, 459:229-236.
13. Salas S., Bartoli C., Deville J.L., et al. Ezrin and alpha-smooth muscle actin are immunohistochemical prognostic markers in conventional osteosarcomas. Virchows Arch 2007, 451:999-1007.
14. Forest M., de Pinieux G. Chondroblastoma and its differential diagnosis. Ann Pathol 2001, 21:468-478.
15. Povysil C., Tomanova R., Matejovsky Z. Muscle-specific actin expression in chondroblastomas. Hum Pathol 1997, 28:316-320.
16. Papachristou D.J., Goodman M.A., Cieply K., et al. Comparison of allelic losses in chondroblastoma and primary chondrosarcoma of bone and correlation with fluorescence in situ hybridization analysis. Hum Pathol 2006, 37:890-898.
17. Soder S., Oliveira A.M., Inwards C.Y., et al. Type II collagen, but not aggrecan expression, distinguishes clear cell chondrosarcoma and chondroblastoma. Pathology 2006, 38:35-38.
18. Salas S., De Pinieux G., Gomez-Brouchet A., et al. Ezrin immunohistochemical expression in cartalaginous tumours: a useful tool for differential diagnosis between chondroblastic osteosarcoma and chondrosarcoma. Virchows Arch 2008, 454:81-87.
19. Romeo S., Eyden B., Prins F.A., et al. TGF-beta1 drives partial myofibroblastic differentiation in chondromyxoid fibroma of bone. J Pathol 2006, 208:26-34.
20. Mirra J.M., Gold R., Downs J., et al. A new histologic approach to the differentiation of enchondroma and chondrosarcoma of the bones. A clinicopathologic analysis of 51 cases. Clin Orthop 1985, 201:214-237.
21. Bovee J.V., Cleton-Jansen AM., Taminiau A.H., et al. Emerging pathways in the development of chondrosarcoma of bone and implications for targeted treatment. Lancet Oncol 2005, 6:599-607.
22. Sutton K.M., Wright M., Fondren G., et al. Cyclooxygenase-2 expression in chondrosarcoma. Oncology 2004, 66:275-280.
23. Ranty M.L., Michot C., Le Pessot F., et al. PAS inclusions, immunoreactive tenascin and proliferative activity in low-grade chondrosarcomas. Pathol Res Pract 2003, 199:29-34.
24. van Beerendonk H.M., Rozeman L.B., Taminiau A.H., et al. Molecular analysis of the INK4A/INK4A-ARF gene locus in conventional (central) chondrosarcomas and enchondromas: indication of an important gene for tumour progression. J Pathol 2004, 202:359-366.
25. Papachristou D.J., Papachristou G.I., Papaefthimiou O.A., et al. The MAPK-AP-1/-Runx2 signaling axes are implicated in chondrosarcoma pathobiology either independently or via up-regulation of VEGF. Histopathology 2005, 47:565-574.
26. Mandahl N., Gustafson P., Mertens F., et al. Cytogenetic aberrations and their prognostic impact in chondrosarcoma. Genes Chromosomes Cancer 2002, 33:188-200.
27. Rozeman L.B., Szuhai K., Schrage Y.M., et al. Array-comparative genomic hybridization of central chondrosarcoma: identification of ribosomal protein S6 and cyclin-dependent kinase 4 as candidate target genes for genomic aberrations. Cancer 2006, 107:380-388.
28. Hameetman L., Kok P., Eilers P.H., et al. The use of Bcl-2 and PTHLH immunohistochemistry in the diagnosis of peripheral chondrosarcoma in a clinicopathological setting. Virchows Arch 2005, 446:430-437.
29. Hameetman L., David G., Yavas A., et al. Decreased EXT expression and intracellular accumulation of heparan sulphate proteoglycan in osteochondromas and peripheral chondrosarcomas. J Pathol 2007, 211:399-409.
30. Sandberg A.A. Decreased EXT expression and intracellular accumulation of heparan sulphate proteoglycan in osteochondromas and peripheral chondrosarcomas. Curr Opin Oncol 2004, 16:342-409.
31. Wehrli B.M., Huang W., De Crombrugghe B., et al. Sox9, a master regulator of chondrogenesis, distinguishes mesenchymal chondrosarcoma from other small blue round cell tumors. Hum Pathol 2003, 34:263-269.
32. Hauben E.I., Jundt G., Cleton-Jansen A.M., et al. Desmoplastic fibroma of bone: an immunohistochemical study including beta-catenin expression and mutational analysis for beta-catenin. Hum Pathol 2005, 36:1025-1030.
33. Bertoni F., Calderoni P., Bacchini P., et al. Benign fibrous histiocytoma of bone. J Bone Joint Surg Am 1986, 68:1225-1230.
34. Tarkkanen M., Larramendy M.L., Bohling T., et al. Malignant fibrous histiocytoma of bone: analysis of genomic imbalances by comparative genomic hybridisation and C-MYC expression by immunohistochemistry. Eur J Cancer 2006, 42:1172-1180.
35. Folpe A.L., Goldblum J.R., Rubin B.P., et al. Morphologic and immunophenotypic diversity in Ewing's family tumors: a study of 66 genetically confirmed cases. Am J Surg Pathol 2005, 29:1025-1033.
36. Tirode F., Laud-Duval K., Prieur A., et al. Mesenchymal stem cell features of Ewings' tumors. Cancer Cell 2007, 11:421-429.
37. Yamaguchi T., Suzuki S., Ishiiwa H., et al. Intraosseous benign notochordal cell tumours: overlooked precursors of classic chordomas?. Histopathology 2004, 44:597-602.
38. Gavril C., Bouvier C., Liprandi A., et al. Pathology of myxoid bone tumors of the skull base. Ann Pathol 2002, 22:259-266.
39. Naka T., Oda Y., Iwamoto Y., Shinohara N., et al. Immunohistochemical analysis of E-cadherin, alpha-catenin, beta-catenin, gamma-catenin, and neural cell adhesion molecule (NCAM) in chordoma. J Clin Pathol 2001, 54:945-950.
40. Vujovic S., Henderson S., Presneau N., et al. Brachyury, a crucial regulator of notochordal development, is a novel biomarker for chordomas. J Pathol 2006, 209:157-165.
41. O'Donnell P., Tirabosco R., Vujovic S., et al. Diagnosing an extra-axial chordoma of the proximal tibia with the help of brachyury, a molecule required for notochordal differentiation. Skeletal Radiol 2007, 36:59-65.
42. Murata A., Fujita T., Kawahara N., et al. Osteoblast lineage properties in giant cell tumors of bone. J Orthop Sci 2005, 10:581-588.
43. Huang L., Teng X.Y., Cheng Y.Y., et al. Expression of preosteoblast markers and Cbfa-1 and Osterix gene transcripts in stromal tumour cells of giant cell tumour of bone. Bone 2004, 34:393-401.
44. Lee C.H., Espinosa I., Jensen K.C., et al. Gene expression profiling identifies p63 as a diagnostic marker for giant cell tumor of the bone. Mod Pathol 2008, 21:531-539.
45. Dickson B.C., Li S.Q., Wunder J.S., et al. Giant cell tumor of bone express P63. Modern Pathol 2008, 21:369-375.
46. Horvai A.E., Kramer M.J., Garcia J.J., et al. Distribution and prognostic significance of human telomerase reverse transcriptase (hTERT) expression in giant-cell tumor of bone. Modern Pathol 2008, 21:423-430.
47. Kahn L.B. Adamantinoma, osteofibrous dysplasia and differentiated adamantinoma. Skeletal Radiol 2003, 32:245-258.
48. Maki M., Athanasou N. Osteofibrous dysplasia and adamantinoma: correlation of proto-oncogene product and matrix protein expression. Hum Pathol 2004, 35:69-74.
49. Oliveira A.M., Perez-Atayde A.R., Dal Cin P., et al. Aneurysmal bone cyst variant translocations upregulate USP6 transcription by promoter swapping with the ZNF9, COL1A1, TRAP150, and OMD genes. Oncogene 2005, 24:3419-3426.
50. Oliveira A.M., Perez-Atayde A.R., Inwards C.Y., et al. USP6 and CDH11 oncogenes identify the neoplastic cell in primary aneurysmal bone cysts and are absent in so-called secondary aneurysmal bone cysts. Am J Pathol 2004, 165:1773-1780.
51. Sukov W.R., Franco M.F., Erickson-Johnson M., et al. Frequency of USP6 rearrangements in myositis ossificans, brown tumor, and cherubism: molecular cytogenetic evidence that a subset of 'myositis ossificans-like lesions' are the early phases in the formation of soft-tissue aneurysmal bone cyst. Skeletal Radiol 2008, 37:321-327.
52. Nilsson M., Domanski H.A., Mertens F., et al. Molecular cytogenetic characterization of recurrent translocation breakpoints in bizarre parosteal osteochondromatous proliferation (Nora's lesion). Hum Pathol 2004, 35:1063-1069.
53. Storlazzi C.T., Wozniak A., Panagopoulos I., et al. Rearrangement of the COL12A1 and COL4A5 genes in subungual exostosis: molecular cytogenetic delineation of the tumor-specific translocation t(X;6)(q13-14;q22). Int J Cancer 2006, 118:1972-1976.
54. Riminucci M., Liu B., Corsi A., et al. The histopathology of fibrous dysplasia of bone in patients with activating mutations of the Gs alpha gene: site-specific patterns and recurrent histological hallmarks. J Pathol 1999, 187:249-258.
55. Marie P.J. Cellular and molecular basis of fibrous dysplasia. Histol Histopathol 2001, 16:981-988.
56. Toyosawa S., Yuki M., Kishino M., et al. Ossifying fibroma vs fibrous dysplasia of the jaw: molecular and immunological characterization. Mod Pathol 2007, 20:389-396.